CP-94253
| Clinical data | |
|---|---|
| Other names | CP94253; CP-94,253 |
| Drug class | Serotonin 5-HT1B receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H19N3O |
| Molar mass | 257.337 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
CP-94253 is a drug of the tetrahydropyridinylpyrrolopyridine family which acts as a potent and selective serotonin 5-HT1B receptor agonist, with approximately 25- and 40-fold selectivity over the closely related serotonin 5-HT1D and 5-HT1A receptors.
It has a range of behavioral effects, based on animal testing. The effects include the following: promoting wakefulness by increasing dopamine release in the brain; reducing food intake and promoting satiety; enhancing the reinforcing effects of cocaine; and possible antidepressant effects. In addition, CP-94253 reduces aggression without causing sedation in rodents.
A 2021 study found that "Regardless of sex, CP94253 decreased cocaine intake after abstinence and during resumption of SA [self-administration] and decreased cue reactivity" suggesting that agonism of the inhibitory 5-HT2B receptors may diminish the cognitive reward of cocaine usage and increased use of the drug without a period of abstinence may be a product of test subjects trying to achieve a previously rewarding experience through larger dosages of cocaine.